Dr Reddy’s Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with Gilead Sciences to produce and distribute HIV drug Lenacapavir in India and 120 LMICs. Lenacapavir, which inhibits HIV at multiple stages, recently showed promising results in prevention trials.
Related Posts
Nifty rallies for 12th day – its longest winning run ever
Sensex and Nifty reached new highs on Friday, driven by positive feedback from global ratings firms about the Indian economy. Buying by India-focused funds after […]
More than 600 linked to terror financing identified this year: Eurasian Group
The Eurasian Group identified over 600 people linked to global terrorist financing networks in 2023. The group discussed challenges in detecting and tracking these financiers, […]
India’s forex kitty spikes $7 billion, surpasses $638 billion
- staff
- February 14, 2025
- 0
India’s foreign exchange reserves increased by $7.654 billion to $638.261 billion in the week ending February 7. This marks the third straight weekly rise, driven […]